Latest Infliximab Stories
-- Hungarian National Registry reports interim results following Inflectra therapy in 90 patients with Crohn's disease and ulcerative colitis BARCELONA and MADRID, Spain, Feb.
-- Major European markets can finally benefit from the availability of Inflectra following the patent expiry of reference product Remicade® (infliximab) LAKE FOREST, Ill., Feb.
DALLAS, February 4, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Ulcerative Colitis - Pipeline Review, H1 2015" to its store.
-33% rate of DAS28-CRP remission or low disease activity reported in Phase 2a cohort- MONROVIA, Calif., Jan. 29, 2015 /PRNewswire/ -- Xencor, Inc.
Sales of Biologics Will Contribute Approximately $2.3 Billion to the UC Market in 2023, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
Drug Developers will Rely on Head-to-Head Clinical Trial Data Against Current Therapies to be Poised to Compete in the Increasingly Crowded TNF-alpha-Refractory Space BURLINGTON, Mass., Nov.
A Different Mechanism of Action from the Currently Available Products is Entyvio's Most Commonly Cited Advantage, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept.
-- HUMIRA is now indicated to treat pediatric patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators
Improved Efficacy and Lower List Price than the Anti-TNFs Will Be the Key Drivers for Prescribing of Emerging Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass.,
Rheumatologists Report that the Vast Majority of RA Patients Who are Candidates for Biologic Treatment Receive a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass.,
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.